Quoin Pharmaceuticals Achieves Target Rapamycin Loadings in Topical Delivery Technologies
Quoin Pharmaceuticals Ltd. has successfully achieved target loading concentrations for its proprietary topical rapamycin delivery technologies, formulating a lotion with 4% w/w and a dermal patch with 5% w/w rapamycin. The company plans to manufacture clinical trial batches in Q4 2025, with testing starting in H1 2026 for conditions lacking FDA-approved treatments. This marks a significant milestone for Quoin’s topical rapamycin programs.
Quoin Pharmaceuticals Ltd. has announced the successful achievement of target loading concentrations for its two proprietary topical rapamycin delivery technologies. The company has formulated a topical lotion with a 4% w/w rapamycin concentration and a dermal patch system with a 5% w/w concentration. These developments mark a significant milestone for Quoin’s topical rapamycin programs. The company plans to begin manufacturing clinical trial and stability batches in the fourth quarter of 2025, with clinical testing set to commence in the first half of 2026. Initial clinical indications will include Microcystic Lymphatic Malformations and Venous Malformations, for which no FDA-approved treatments currently exist. The results have been announced by the company and clinical testing will be conducted in the future. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
